Hidonac Antídoto

Hidonac Antídoto is an intravenous solution for injection that contains the mucolytic agent acetylcysteine. The product is supplied in a standard strength (exact concentration not disclosed) and is marketed in the European Union as a prescription‑only medication for specific clinical situations. It is intended for use under medical supervision and is classified under ATC code N07BC01 as both a mucolytic and an antidote for acetaminophen toxicity.

Hidonac Antídoto is prescribed when rapid reduction of mucus viscosity or protection against acetaminophen‑induced liver injury is required. Clinical situations include: - Treatment of confirmed acetaminophen (paracetamol) overdose to prevent hepatic damage. - Adjunctive therapy for acute respiratory conditions with thick secretions, such as chronic bronchitis. - Supportive care in cystic fibrosis patients during pulmonary exacerbations. - Use in intensive‑care settings for ventilated patients needing mucolysis. - Administration prior to contrast imaging in patients at risk of contrast‑induced nephropathy (off‑label in some regions).

Adverse reactions to Hidonac Antídoto are generally related to the intravenous route and the pharmacologic activity of acetylcysteine.

Common: - Mild nausea or vomiting occurring during or shortly after infusion. - Transient flushing or erythema at the injection site. - Low‑grade headache that resolves without intervention. - Slight increase in bronchial secretions leading to temporary cough.

Serious: - Anaphylactoid reactions such as hypotension, bronchospasm, or angioedema. - Severe rash or urticaria indicating hypersensitivity. - Acute hepatic enzyme elevation in patients with pre‑existing liver disease. - Pulmonary edema in high‑risk patients receiving large volumes.

When using Hidonac Antídoto, clinicians should evaluate patient history and monitor for specific conditions that may increase risk of adverse outcomes. - Assess liver function before administration in suspected acetaminophen overdose. - Verify no known hypersensitivity to acetylcysteine or related compounds. - Use caution in patients with asthma or reactive airway disease due to possible bronchospasm. - Adjust infusion rate in individuals with cardiovascular instability. - Avoid rapid bolus administration; prefer controlled infusion to reduce anaphylactoid risk. - Monitor vital signs and oxygen saturation throughout the infusion.

Acetylcysteine may alter the pharmacokinetics or safety profile of several co‑administered agents; awareness of these interactions helps prevent complications.

Avoid: - Concomitant use with nitroglycerin or other vasodilators that may exacerbate hypotension. - Simultaneous administration of activated charcoal, which can bind acetylcysteine and reduce its effectiveness.

Use with caution: - Anticoagulants such as warfarin, because changes in plasma volume may affect INR monitoring. - Loop diuretics, as rapid fluid shifts can influence electrolyte balance. - Other hepatotoxic drugs, where added liver stress warrants closer hepatic function testing. - Cimetidine, because it may reduce the conversion of acetylcysteine to its active metabolite.